SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

The Sentara Health Plans Oncology Program is administered by OncoHealth

❖ **For any oncology indications**, the most efficient way to submit a prior authorization request is through the **OncoHealth OneUM Provider Portal** at https://oneum.oncohealth.us. Fax to **1-800-264-6128.** OncoHealth can also be contacted by Phone: 1-888-916-2616.

Drug Requested: Gonadotropin-releasing Hormone Agonists (GnRH) (Medical)

Preferred Drugs		
❑ **Camcevi™** (leuprolide) **42 mg (6-month) (J1952)**	❑ **Eligard®** (leuprolide) **22.5 mg (3-month) (J9217)**	❑ **Eligard®** (leuprolide) **30 mg (4-month) (J9217)**
❑ **Eligard®** (leuprolide) **45 mg (6-month) (J9217)**	❑ **Leuprolide Depot 22.5 mg (3-month) [vial] (J1954)**	❑ **Lupron Depot®** (leuprolide acetate) **11.25 mg (3-month) (J9217)**
❑ **Lupron Depot®** (leuprolide acetate) **22.5 mg (3-month) (J9217)**	❑ **Lupron Depot®** (leuprolide acetate) **30 mg (4-month) (J9217)**	❑ **Lupron Depot®** (leuprolide acetate) **45 mg (6-month) (J9217)**
❑ **Lupron Depot-Ped®** (leuprolide acetate) **11.25 mg (3-month) (J1950)**	❑ **Lupron Depot-Ped®** (leuprolide acetate) **30 mg (3- month) (J1950)**	❑ **Lupron Depot-Ped®** (leuprolide acetate) **45 mg (6-month) (J1950)**
❑ **Lutrate Depot** (leuprolide acetate) **22.5 mg (3- month) [vial] (J1954)**	❑ **Supprelin® LA** (histrelin) **50 mg (12-month) (J9226)** *Requires authorization under medical benefit	❑ **Trelstar®** (triptorelin pamoate) **11.25 mg (3-month) (J3315)**
❑ **Trelstar®** (triptorelin pamoate) **22.5 mg (3-month) (J3315)**	❑ **Vantas™** (histrelin) **50mg (12-month) (J9225)** *Requires authorization under medical benefit	
Non-Preferred Drugs		
❑ **Eligard®** (leuprolide) **7.5 mg (1-month) (J9217)**	❑ **Fensolvi®** (leuprolide) **45 mg (6-month) (J1951)**	❑ **Leuprolide acetate 5 mg/mL SubQ Solution (J9218)**
❑ **Lupron Depot®** (leuprolide acetate) **3.75 mg (1-month) (J1950)**	❑ **Lupron Depot®** (leuprolide acetate) **7.5 mg (1-month) (J9217)**	❑ **Lupron Depot-Ped®** (leuprolide acetate) **7.5 mg (1-month) (J1950)**
❑ **Lupron Depot-Ped®** (leuprolide acetate) **11.25 mg (1- month) (J1950)**	❑ **Lupron Depot-Ped®** (leuprolide acetate) **15 mg (1- month) (J1950)**	❑ **Trelstar®** (triptorelin pamoate) **3.75 mg (1-month) (J3315)**

(Continued on next page)

Non-Preferred Drugs		
❑ **Triptodur®** (triptorelin) **22.5 mg (6-month) (J3316)**	❑ **Vabrinty™**(subcutaneous leuprolide acetate; ***prostate cancer only***) **(J3490)*** ❑ **7.5 mg (1-month)** ❑ **22.5 mg (3-month)** ❑ **30 mg (4-month)** ❑ **45 mg (6-month)**	❑ **Zoladex®** (goserelin) **3.6 mg (1-month) (J9202)** *Requires authorization under medical benefit
❑ **Zoladex®** (goserelin) **10.8 mg (3-month) (J9202)** *Requires authorization under medical benefit		

***Vabrinty™** (subcutaneous leuprolide acetate) is an authorized generic for Eligard. The FDA defines "authorized generic" to describe an approved brand name drug that is marketed without the brand name on its label. Other than the fact that it does not have the brand name on its label, it is the same drug product; therefore, an authorized generic is considered to be therapeutically equivalent to its brand-name drug because it is the same drug [https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/fda-list-authorized-generic-drugs].

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

(Continued on next page)

A. Length of Authorization:

- Endometriosis: Coverage will be provided for 6 months and is eligible for conditional 12-month renewal
- Uterine leiomyomata (fibroids): Coverage will be provided for 6 months and is eligible for conditional 12-month renewal
- Gender Dysphoria & Disorders of Sex Development: Coverage will be provided for 12 months and may be renewed annually
- All other indications: Coverage will be provided for 12 months and may be renewed annually

B. Quantity Limits:

Drug Name	Strength	Quantity	Day Supply
Camcevi	42 mg	1 injection	180 days
Leuprolide acetate SubQ solution	5 mg/mL (1 mg/0.2 mL multi-dose vial)	2 vials	28 days
Leuprolide Depot 3-month	22.5 mg	1 vial	84 days
Lupron Depot 1-month	3.75 mg, 7.5 mg	1 injection	28 days
Lupron Depot 3-month	11.25 mg, 22.5 mg	1 injection	84 days
Lupron Depot 4-month	30 mg	1 injection	112 days
Lupron Depot 6-month	45 mg	1 injection	168 days
Lupron Depot-Ped 1-month	7.5 mg, 11.25 mg, 15 mg	1 injection	28 days
Lupron Depot-Ped 3-month	11.25 mg, 30 mg	1 injection	84 days
Lupron Depot-Ped 6-month	45 mg	1 injection	168 days
Lutrate Depot 3-month	22.5 mg	1 vial	84 days
Eligard 1-month	7.5 mg	1 injection	28 days
Eligard 3-month	22.5 mg	1 injection	84 days
Eligard 4-month	30 mg	1 injection	112 days
Eligard 6-month	45 mg	1 injection	168 days
Fensolvi 6-month	45 mg	1 injection	168 days
Trelstar 1-month	3.75 mg	1 injection	28 days
Trelstar 3-month	11.25 mg	1 injection	84 days
Trelstar 6-month	22.5 mg	1 injection	168 days
Triptodur 6-month	22.5 mg	1 injection	168 days
Supprelin LA	12-month	1 implant	365 days
Vabrinty 1-month	7.5 mg	1 injection	28 days
Vabrinty 3-month	22.5 mg	1 injection	84 days
Vabrinty 4-month	30 mg	1 injection	112 days
Vabrinty 6-month	45 mg	1 injection	168 days
Vantas	50 mg	1 implant	365 days
Zoladex 1-month	3.6 mg	1 implant	28 days
Zoladex 3-month	10.8 mg	1 implant	84 days

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Diagnosis: Prostate Cancer

Initial Authorization and Reauthorization

- ❑ Member's medical diagnosis, treatment regimen (including dose and line-of-therapy), and support of therapy meets Sentara Health Plans Chemotherapy Policy: https://www.sentarahealthplans.com/en/providers/clinical-reference/medical-policies/categories/medical
- ❑ If requesting Vabrinty, the member must meet **ALL** the following, and the provider must submit supporting documentation:
  - ❑ Trial of therapy and noted progression of disease with Lupron Depot
  - ❑ Must have had a trial of Eligard® and **NOT** have experienced disease progression
  - ❑ Provider **MUST** submit a completed MedWatch form documenting why Eligard® cannot be used in therapy

❑ Diagnosis: Gender Identity/Gender Dysphoria

Initial Authorization

- ❑ Member is 18 years of age or older and has a diagnosis of gender dysphoria

  Note: Gender Dysphoria Diagnosis is an **Excluded Benefit for members under 18** years of age.

  In accordance with a new federal rule (2026-16508 (91 FR 52406), the Department of Medical Assistance Services (DMAS) will no longer cover gender-affirming procedures, including certain drugs/hormone therapies, to youth enrolled in Medicaid and the Children's Health Insurance Program (CHIP) beginning **October 13, 2026**. These restrictions also prohibit states' use of the federal Medicaid Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) pathway to provide coverage of these services to children under 18.
- ❑ Provider attests member has the capacity to make informed treatment decisions and has consented to treatment after discussion of the potential benefits and risks
- ❑ Member has been assessed and diagnosed with gender dysphoria according to DSM-V criteria, by **ONE** of the following provider types:
  - ❑ A licensed mental health provider
  - ❑ An endocrinologist
  - ❑ A gender dysphoria-informed hormone prescriber, defined as a provider competent in the assessment of gender dysphoria who practices in conjunction with a multidisciplinary gender dysphoria care team

(Continued on next page)

- ❑ Medication is prescribed by, or in consultation with an endocrinologist or other medical provider experienced in gender dysphoria hormone therapy
- ❑ Provider attests coexisting behavioral health and medical comorbidities or social problems that may interfere with diagnostic procedures or treatment are being appropriately treated and are not causing symptoms of gender dysphoria
- ❑ Member has experienced puberty development to at least **ONE** of the following:
  - ❑ Tanner stage 2 (stage 2 through 4)
  - ❑ Lab values for Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), and the endogenous sex hormones consistent with at least Tanner stage 2 **(must submit documentation)**
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above

❑ Diagnosis: Disorders of Sex Development

Initial Authorization

- ❑ Member has **ONE** of the following diagnoses for disorders of sex development **(must submit documentation)**:
  - ❑ Q56.0-Q56.4 (sex differentiation disorders)
  - ❑ Q97.x (Other sex chromosome abnormalities, female phenotype)
  - ❑ Q99.0 (46,XX/46,XY chimerism)
  - ❑ E25.X (Adrenogenital disorders)
  - ❑ E30.0-E30.9 (puberty disorders)
  - ❑ E34.5 (Androgen insensitivity syndrome)

❑ Diagnosis: Central Precocious Puberty

Initial Authorization

- ❑ Member is less than 13 years of age
- ❑ Onset of secondary sexual characteristics associated with pubertal pituitary gonadotropin activation, occurring earlier than age 8 for girls and age 9 for boys **(submit documentation, progress notes, medical documentation recording physical changes, Tanner staging)**
- ❑ Diagnosis of central precocious puberty is confirmed by **ALL** the following:
  - ❑ Laboratory documentation of pubertal gonadal sex steroid level
  - ❑ Pubertal luteinizing hormone response simulation by native GnRH **[Laboratory documentation demonstrating basal LH (>0.3 IU/L), and peak stimulated LH (>4-6 IU/L)]**
  - ❑ X-Ray results of the estimated bone age of the non-dominant wrist and hand greater than 2 standard deviations beyond chronological age **(submit laboratory and x-ray documentation)**

(Continued on next page)

- ❑ A tumor has been ruled out by lab tests such as diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), and human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor)
- ❑ Medication will **NOT** be used in combination with growth hormone therapy
- ❑ The quantity (dose) requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above

❑ Diagnosis: Gynecological Indications

Initial Authorization

- ❑ Member is 18 years of age or older
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above
- ❑ Treatment is being prescribed by or in consultation with a specialist in obstetrics/gynecology
- ❑ Select **ONE** of the following indications for use:
  - ❑ **FOR UTERINE LEIOMYOMATA, FIBROIDS** (requires chart notes documenting symptomology/pelvic exam, transvaginal ultrasonography, sono-hysterography):
    - ❑ Member is premenopausal
    - ❑ Member has uterine leiomyomas (fibroids)
    - ❑ Member is using for the management of heavy menstrual bleeding
    - ❑ Member has history of inadequate response to **ALL** three of the following therapies for at least three (3) months each **(must submit chart notes documentation of all therapy failures)**:
      - ❑ Oral contraceptives OR a selective progesterone receptor modulator, OR intrauterine device
      - ❑ NSAIDs (non-steroidal anti-inflammatory drugs)
      - ❑ tranexamic acid 650 mg

        OR
      - ❑ Member has had surgery for uterine fibroids (i.e. ablation, myomectomy) and has persistent symptoms **(must submit documentation of date/type of surgery or procedure)**
    - ❑ The quantity (dose) and administration frequency requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met
  - ❑ **FOR ENDOMETRIOSIS** (requires chart notes detailing and recording treatment plan and/or symptomology of chronic pelvic pain (defined as noncyclical pain lasting 6 or more months that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks, and is of sufficient severity to cause functional disability or lead to medical care), amenorrhea, preoperative ablation treatment):
    - ❑ Member is premenopausal
    - ❑ Member has a diagnosis of moderate to severe pain associated with endometriosis

(Continued on next page)

- ❑ Diagnosis of endometriosis has been confirmed by direct visualization during surgery and/or histology
- ❑ Member does **NOT** have any contraindications to therapy including osteoporosis, severe hepatic impairment/disease, or concomitant use of hormonal contraceptives
- ❑ Member has history of inadequate response, intolerance or contraindication, to the following therapies for at least three (3) months each **(must submit chart note documentation of all therapy failures)**:
  - ❑ NSAIDs (non-steroidal anti-inflammatory drugs)
  - ❑ Combination (estrogen/progesterone) oral contraceptive
  - ❑ Progestins

  OR
  - ❑ Member has had surgical ablation to prevent recurrence
- ❑ The quantity (dose) and administration frequency requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met

Reauthorization: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member continues to meet all initial criteria

❑ **Diagnosis: Central Precocious Puberty** (Please submit chart notes and other supporting documents)

- ❑ Member is **NOT** over the age of 13
- ❑ Member has experienced disease response as indicated by lack of progression or stabilization of secondary sexual characteristics, decrease in growth velocity and bone age advancement, and improvement in final height prediction
- ❑ Member has experienced an absence of unacceptable toxicity from the drug (e.g., convulsions, development or worsening of psychiatric symptoms)

❑ **Diagnosis: Gynecological Indications** (Please submit chart notes and other supporting documents)

- ❑ Total duration of therapy (initial plus re-treatment for symptom recurrence) should not exceed 12 months, **AND** will be used in combination with add-back therapy, unless clinically contraindicated

OR

(Continued on next page)

- ❑ The member's medical history and medical condition's current status requires longer treatment duration than otherwise recommended in published compendia/FDA labeling.

  Please provide an explanation along with any pertinent progress notes of medical condition including recorded recurrence of symptoms, procedure/exam results:

  _____

  _____

  _____

  _____

  _____

  _____

AND

- ❑ Prescriber will order and review a bone density assessment prior to re-treatment

Medication being provided by: Please check applicable box below.

- ❑ **Location/site of drug administration:** _____

  NPI or DEA # of administering location: _____

OR

- ❑ **Specialty Pharmacy**

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

***Approved by Pharmacy and Therapeutics Committee**: ~~3/17/2022; 5/22/2025;~~ **9/25/2025**
REVISED/UPDATED/REFORMATTED: ~~5/4/2022; 6/21/2022; 7/13/2022; 10/21/2022; 7/31/2024; 8/27/2024; 12/20/2024; 2/28/2025; 4/24/2025; 6/9/2025; 8/13/2025; 10/23/2025;~~ **10/16/2026**